Pharmaceuticals News and Research

RSS

Drastic market changes with MRI contrast media and PET radiopharmaceuticals emerging as most promising segments

Significant changes in the European contrast media and radiopharmaceuticals market are seeing some segments experience growth while others near saturation.

21 Oct 2004

Cost cutting measures and patent expirations to propel the European generics and biogenerics market

The upcoming spate of patent expirations bodes well for the European generics market. The growing loss of patent protection on blockbuster brands over the next few years, coupled with the rising need to contain spiralling healthcare costs, is set to provide a fillip to market expansion.

19 Oct 2004

Study will evaluate arsenic exposure from the environment and its potential carcinogenic effects

The National Cancer Institute has awarded the Arizona Cancer Center at the University of Arizona Health Sciences Center a three-year grant to evaluate associations between elevated arsenic exposure and cancer incidence in Arizona and Mexico.

19 Oct 2004

Chiron responds to FDA announcement

Chiron Corporation last Friday provided the following statement in response to an announcement by U.S. health officials on the current influenza vaccine situation.

18 Oct 2004

Researchers have developed a novel drug-antidote pair

In a discovery that could give physicians more control over the actions of medications, researchers at Duke University Medical Center have developed a novel drug pair – a potent anti-coagulant with a matched "antidote."

18 Oct 2004

Asthma research company Synairgen to float on London's Alternative Investment Market

A spin-out company from the University of Southampton specialising in finding and out-licensing treatments for chronic bronchitis (COPD) and the severest forms of asthma, is about to seek a listing on London's Alternative Investment Market (AIM).

13 Oct 2004

Teva Pharmaceutical granted FDA approval for Flumazenil injection

Teva Pharmaceutical Industries Ltd. has announced that the U.S. Food and Drug Administration has granted final approval for the Company’s ANDA for Flumazenil Injection, 0.1 mg/mL. Commercial marketing of this product will begin immediately.

13 Oct 2004

Ecstasy study identifies potentially lethal combination

Some ecstasy users are using a variety of pharmaceutical drugs to increase the effect of ecstasy or to combat the negative effects of the drug a new study released today has found. The results suggest that some of these combinations are potentially lethal and could result in 'serotonin syndrome'.

12 Oct 2004

Protein called Mrp4 blocks the access of the anti-cancer drug topotecan into the brain

A protein called Mrp4 blocks the access of the anti-cancer drug topotecan into the brain by transporting this agent back into the bloodstream, thus reducing the ability of this agent to reach tumors.

11 Oct 2004

Carbon nanotubes offer a new approach to gene therapy

Many genes that are related to particular diseases have now been identified. Scientists are trying to use this knowledge to treat diseases.

11 Oct 2004

Pharmacists respond to unprecedented demand for the flu vaccine in the wake of the current shortage

Pharmacists are responding to unprecedented demand for the flu vaccine in the wake of the current shortage. The pharmacist is on the front line in addressing consumers’ questions and concerns about the availability of the vaccine and in helping Americans understand the CDC’s priorities for administration of the immunization.

10 Oct 2004

Low-dose estrogen therapy significantly reduced the progression of fatty buildup in the arteries leading to the heart

“We’ve shown that you can get the same reduction in coronary artery atherosclerosis with standard-dose or low-dose estrogen,” said Thomas B. Clarkson, D.V.M., one of the investigators. “It is very significant.”

10 Oct 2004

Flu vaccine shortage highlights need to accelerate the approval of affordable generic biopharmaceuticals and vaccines

Following the announcement that the nation is facing a flu vaccine shortage this year, the Generic Pharmaceutical Association (GPhA) renewed its call for the Food and Drug Administration (FDA) and Congress to move forward to accelerate the approval of affordable generic biopharmaceuticals and vaccines.

8 Oct 2004

New targets for combating infections in medical implants

Navarre researcher, Jaione Valle Turrillas, has identified two genes that could help as targets for pharmaceutical drugs that fight the Staphylococcus aureus bacteria - one of the bacteria which causes most infections in medical implants.

8 Oct 2004

Vioxx: an unequal partnership between safety and efficacy

Last week’s dramatic withdrawal of the COX-2 inhibitor rofecoxib (Vioxx) is discussed in this week’s lead editorial in THE LANCET, which comments that more vigilant drug licensing is vital to prevent the endangering of patients’ health.

7 Oct 2004

The search for the Holy Grail for dieters is on

Starting this month Canadian and British scientists will begin collaborating on a study to examine human appetite- controlling hormones with a view to finding out what will increase PYY, a powerful hormone in the human body which dramatically diminishes appetite.

7 Oct 2004

International symposium will focus on curing mesothelioma

A lethal, but long-overlooked cancer will take a major step out of the shadows next week, as The Mesothelioma Applied Research Foundation convenes the First International Symposium on Malignant Mesothelioma.

6 Oct 2004

Eight out of ten women take some form of therapeutic drugs during pregnancy

The advice from the British National Formulary (British Medical Association and the Royal Pharmaceutical Society of Great Britain) is that all drugs should be avoided if possible during the first three months – and only prescribed at all if the benefits to the mother outweigh the risk to the foetus.

6 Oct 2004

RiboNovix secures license to novel anti-infective discovery technology from Wayne State University

New biotechnology company, RiboNovix, Inc., is addressing the worsening problem of antibiotic-resistant bacteria by developing new anti-infectives that are less susceptible to drug resistance.

5 Oct 2004

Natural alternatives to osteoarthritis drug

The recall of Vioxx should come as a major sign of the need to look for safer alternatives for osteoarthritis treatment, according to the Director of the Australian Centre for complementary Medicine Education and Research (ACCMER), Professor Stephen Myers.